![]() ![]() Arising from the blockade of L-type calcium channels in detrusor muscles, CCBs are associated with increased duration for bladder maximum contraction, maximal rate of emptying and rate of filling. This occurs as a result of its interference with bladder contraction. This will facilitate enhanced quality of life in patients with BPH.Ĭalcium channel blockers (CCBs) are commonly used antihypertensive medicines, and are associated with the development of lower urinary tract symptoms (LUTS). Patients should also be counselled to notify their healthcare provider of unusual urinary symptoms during CCB use. Patients on CCBs should be routinely reviewed for any potential precipitation or aggravation of LUTS. Therefore, it is essential to identify persons with BPH prior to commencement of therapy with CCBs. Persons at high risk of LUTS such as in BPH, may benefit from other classes of antihypertensive drugs. This suggests a potential aggravation of BPH symptoms with the use of CCBs. Hence, CCBs are associated with precipitation or aggravation of urinary storage and voiding symptoms, which are also common symptoms of BPH. The inhibition of calcium channels by CCBs interferes with influx of extracellular Ca 2+ into the detrusor muscle, which interferes with bladder contraction and relaxation. Selected studies were assessed for content related to CCBs, BPH and LUTS, and the most relevant reports were included. Relevant studies were also extracted from references of identified studies. Main body of the abstractĪ search of databases of PubMed, Web of science, Hinari, and Google scholar was performed using several keywords. This review summarised and synthesised relevant information and recent advances to improve clinical knowledge on the role of CCBs in LUTS, BPH symptoms and health-related quality of life. Benign prostatic hyperplasia (BPH) and the use of CCBs are common in older persons, and are also associated with lower urinary tract symptoms (LUTS). ![]()
0 Comments
Leave a Reply. |